文献速递妇科

多聚二磷酸腺苷核糖聚合酶抑制剂在社区肿瘤 PRACTICE 中的真实世界经验

Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
PubMed 文献 · Gynecol Oncol · 2020-08-15

该回顾性图表综述描述了2016年12月至2018年11月间十二位妇科肿瘤医生在大型社区肿瘤实践中为复发性卵巢癌、原发性腹膜癌或输卵管癌患者处方奥拉帕利、尼拉帕利或芦卡帕利进行维持治疗或治疗的真实世界经验,共纳入47例患者和506个PARP抑制剂周期,评估了临床与财务负担。

要点

  • 共47例患者和506个PARP抑制剂周期被纳入分析。
  • 毒性导致剂量中断、减量和停药的比例分别为69%、63%和29%。
  • PARP抑制剂治疗平均每周期费用为8018美元。

核心结论

  • 尽管毒性特征与随机临床试验相似,但该真实世界经验显示为管理毒性而进行的剂量调整和停药比既往报道更多。
  • PARP抑制剂的临床和财务负担可能显著,未来研究应评估对患者结局的影响。

研究设计与样本

  • 回顾性图表综述,纳入2016年12月至2018年11月间十二位妇科肿瘤医生在大型社区肿瘤实践中为复发性卵巢癌、原发性腹膜癌或输卵管癌患者处方奥拉帕利、尼拉帕利或芦卡帕利进行维持治疗或治疗的患者。
  • 共识别47例患者和506个PARP抑制剂周期,其中一个PARP周期定义为28天。

主要发现

  • 共47例患者和506个PARP抑制剂周期(奥拉帕利122个周期,24%;芦卡帕利89个周期,18%;尼拉帕利294个周期,58%)。
  • 3级及以上不良事件发生率与既往报道相似。
  • 毒性导致剂量中断、减量和停药的比例分别为69%、63%和29%。
  • 剂量中断在尼拉帕利中最频繁,但导致的停药较少(p值0.01)。
  • 平均使用持续时间为7.46个周期(奥拉帕利10.52个周期,芦卡帕利4.68个周期,尼拉帕利7.34个周期);PARP抑制剂治疗平均每周期费用为8018美元。

关键数值与推荐

  • 3级及以上不良事件发生率与既往报道相似。
  • 毒性导致剂量中断、减量和停药的比例分别为69%、63%和29%。
  • 剂量中断在尼拉帕利中最频繁,但导致的停药较少(p值0.01)。
  • 平均使用持续时间为7.46个周期(奥拉帕利10.52个周期,芦卡帕利4.68个周期,尼拉帕利7.34个周期)。
  • PARP抑制剂治疗平均每周期费用为8018美元;共记录711次电话(呼叫率1.4次/周期)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to describe the real-world experience, including the clinical and financial burden, associated with PARP inhibitors in a large community oncology practice. METHODS: Retrospective chart review identified patients prescribed olaparib, niraparib or rucaparib for maintenance therapy or treatment of recurrent ovarian, primary peritoneal or fallopian tube cancer across twelve gynecologic oncologists between December 2016 and November 2018. Demographic, financial and clinical data were extracted. One PARP cycle was defined as a single 28-day period. For patients treated with more than one PARPi, each course was described separately. RESULTS: A total of 47 patients and 506 PARP cycles were identified (122 olaparib, 24%; 89 rucaparib, 18%; 294 niraparib, 58%). Incidence of grade ≥ 3 adverse events were similar to previously reported. Toxicity resulted in dose interruption, reduction and discontinuation in 69%, 63% and 29% respectively. Dose interruptions were most frequent for niraparib but resulted in fewer discontinuations (p-value 0.01). Mean duration of use was 7.46 cycles (olaparib 10.52, rucaparib 4.68, niraparib 7.34). Average cost of PARPi therapy was $8018 per cycle. A total of 711 phone calls were documented (call rate 1.4 calls/cycle) with the highest call volume required for care coordination, lab results and toxicity management. CONCLUSIONS: Although the toxicity profile was similar to randomized clinical trials, this real-world experience demonstrated more dose modifications and discontinuations for toxicity management than previously reported. Furthermore, the clinical and financial burden of PARP inhibitors may be significant and future studies should assess the impact on patient outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Eakin CM, Ewongwo A, Pendleton L, et al. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecol Oncol. 2020. PMID: 32811682. doi:10.1016/j.ygyno.2020.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。